Other
Deborah Yurgelun-Todd
Total Trials
3
Recruiting
0
Active
0
Completed
2
Success Rate
66.7%-20% vs avg
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 80/100
Failure Rate
33.3%
1 terminated/withdrawn out of 3 trials
Success Rate
66.7%
-19.8% vs industry average
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
50%
1 of 2 completed trials have results
Key Signals
1 with results
Enrollment Performance
Analytics
N/A
2(66.7%)
Early Phase 1
1(33.3%)
3Total
N/A(2)
Early Phase 1(1)
Activity Timeline
Global Presence
Loading network data...
Clinical Trials (3)
Showing 3 of 3 trials
NCT01502813Not ApplicableCompleted
Citicoline, Creatine, and Omega-3 Effects in Middle Age Women
Role: lead
NCT01582113Early Phase 1Completed
Cognizin Citicoline Dosing in a Healthy Adolescent Male Population
Role: lead
NCT01515917Not ApplicableWithdrawn
Citicoline and Omega-3 Fatty Acid Effects in Veterans With Traumatic Brain Injury (TBI)
Role: lead
All 3 trials loaded